Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Sep 30, 2021

Roche Announces Results of REGN-COV 2066 Study for Ronapreve for the Treatment in Patients Hospitalized with COVID-19

TOKYO, September 30, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release today regarding results of REGN-COV 2066 study for the anti-SARS-CoV-2 monoclonal antibody Ronapreve [generic name: casirivimab (genetical recombination)/imdevimab (genetical recombination)] for the treatment in adult patients hospitalized with COVID-19.

Please refer to the link below for details of the press release:
Phase II/III trial shows Ronapreve (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
https://www.roche.com/media/releases/med-cor-2021-09-30.htm

Trademarks used or mentioned in this release are protected by laws.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top